Rilonacept significantly reduces gout flares, study suggests
Thursday, January 5, 2012 - 12:31
in Health & Medicine
A phase II clinical trial found that rilonacept, an inhibitor of the protein interleukin-1, significantly reduced acute gout flares that occur when initiating uric acid-lowering therapy. Results of the trial -- the first placebo-controlled study investigating IL-1 targeted therapy in prevention of gout flares -- show rilonacept to be generally well tolerated with no serious infections or treatment-related serious adverse events reported.